iNtRON Biopharma

iNtRON Biotechnology is a South Korean clinical-stage biopharmaceutical company specializing in the development of bacteriophage-based therapeutics and endolysin technologies. The company focuses on addressing the global challenge of antibiotic-resistant bacterial infections through its proprietary itLysin platform, which engineers bacteriophage-derived enzymes to selectively destroy pathogenic bacteria. Its lead candidate, SAL200, is a first-in-class endolysin-based drug for the treatment of Staphylococcus aureus bacteremia and has reached Phase 2 clinical trials. Beyond human health, iNtRON leverages its phage technology for animal health and food safety applications, positioning itself as a leader in the 'post-antibiotic' era.